Panitumumab - Purchase of Pharmaceutical Substance

This tender concerns the procurement of the pharmaceutical substance Panitumumab. The contracting authority is seeking to acquire this active pharmaceutical ingredient. The tender documents, which are referenced for detailed information, outline the grounds for exclusion and qualification criteria that potential suppliers must meet. These criteria are essential for ensuring that only eligible and capable entities can participate in the procurement process. The purchase of Panitumumab is likely for medical treatment purposes, and adherence to strict quality and regulatory standards is paramount. Bidders are required to carefully review the tender documentation to understand the specific requirements regarding the substance's specifications, packaging, delivery, and any relevant certifications or approvals. The process aims to secure a reliable supply of this critical pharmaceutical product, ensuring patient access and adherence to healthcare standards.

This is a supplies contract in the health and medical services sector, with a focus on Pharmaceuticals. Located in Estonia, Europe, this opportunity is open to firms and consortiums.

Published through TED - Tenders Electronic Daily (EU), a national government procurement portal. Public procurement tenders follow the country's national bidding regulations and may have specific eligibility and documentation requirements for the supply of goods in the health and medical services sector. Supply contracts typically require bidders to demonstrate product compliance with technical specifications, delivery capacity, and relevant certifications. This contract has already been awarded. The information is published for transparency and market intelligence purposes.